NICE approves daily tablet for advanced breast cancer

Getty/alvarez

By Sarah Lowden

Elacestrant has been approved for treating a type of advanced breast cancer on the NHS in England, the National Institute for Health and Care Excellence has confirmed.

The daily tablet, also known as Korserdu and made by Menarini Stemline, can be used for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer with an activating ESR1 mutation.